Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $123.97, giving the company a market capitalization of 154.31B. It carries a P/E multiple of 17.09 and pays a dividend yield of 2.54%.
During the trading session on 2026-06-16, Gilead Sciences(GILD) shares reached a daily high of $125.56 and a low of $122.70. At a current price of $123.97, the stock is +1.0% higher than the low and still -1.3% under the high.
Trading activity shows a volume of 6.59M, compared to an average daily volume of 9.26M.
The stock's 52-week range extends from a low of $104.46 to a high of $157.29.
The stock's 52-week range extends from a low of $104.46 to a high of $157.29.
GILD News
Gilead (GILD) Sciences announced the U.S. FDA accepted its supplemental New Drug Application for Yeztugo 300-mg tablet as a potential once-weekly oral formulati...
Gilead Sciences (NasdaqGS:GILD) has donated remdesivir to Uganda to support the response to an Ebola Bundibugyo virus disease outbreak. The donation forms part...
Gilead Sciences (GILD) announced an update on their ongoing clinical study. Gilead Sciences has launched a Phase 2 study titled “A Phase 2, Open Label, Multice...
Analyst ratings
80%
of 30 ratingsMore GILD News
Gilead (GILD) Sciences announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support resp...
Gilead Sciences and Merck recently reported that their Phase 3 ISLEND-1 and ISLEND-2 trials for a once-weekly oral HIV regimen met primary efficacy and safety g...
While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability o...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.